Structure-based design of oxygen-linked macrocyclic kinase inhibitors: discovery of SB1518 and SB1578, potent inhibitors of Janus kinase 2 (JAK2) and Fms-like tyrosine kinase-3 (FLT3)-Reference-Cited by-同舟云学术

Structure-based design of oxygen-linked macrocyclic kinase inhibitors: discovery of SB1518 and SB1578, potent inhibitors of Janus kinase 2 (JAK2) and Fms-like tyrosine kinase-3 (FLT3)

Published:2012-04 Issue:4 Volume:26 Page:437-450
ISSN:0920-654X
Container-title:Journal of Computer-Aided Molecular Design
language:en
Short-container-title:J Comput Aided Mol Des

Author:

Poulsen Anders,William Anthony,Blanchard Stéphanie,Lee Angeline,Nagaraj Harish,Wang Haishan,Teo Eeling,Tan Evelyn,Goh Kee Chuan,Dymock Brian

Publisher

Springer Science and Business Media LLC

Subject

Physical and Theoretical Chemistry,Computer Science Applications,Drug Discovery

Link

http://link.springer.com/content/pdf/10.1007/s10822-012-9572-z.pdf

Reference40 articles.

1. Rawlings JS, Rosler KM, Harrison DA (2004) J Cell Sci 117:1281

2. Bennett M, Stroncek DF (2006) J Transl Med 4:41

3. Harpur AG, Andres AC, Ziemiecki A, Aston RR, Wilks AF (1992) Oncogene 7:1347

4. Peeters P, Raynaud SD, Cools J, Wlodarska I, Grosgeorge J, Philip P, Monpoux F, Van Rompaey L, Baens M, Van den Berghe H, Marynen P (1997) Blood 90:2535

5. Levine RL, Pardanani A, Tefferi A, Gilliland DG (2007) Nat Rev Cancer 7:673

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A comprehensive review of new small molecule drugs approved by the FDA in 2022: Advance and prospect;European Journal of Medicinal Chemistry;2024-11

2. A review on macrocyclic kinase inhibitors in clinical trials;International Journal of Pharmaceutical Chemistry and Analysis;2024-07-15

3. Structure-property Relationships Reported for the New Drugs Approved in 2022;Mini-Reviews in Medicinal Chemistry;2024-02

4. Next-Generation JAK2 Inhibitors for the Treatment of Myeloproliferative Neoplasms: Lessons from Structure-Based Drug Discovery Approaches;Blood Cancer Discovery;2023-07-27

5. Pacritinib inhibits glucose consumption in squamous cell lung cancer cells by targeting FLT3;Scientific Reports;2023-01-25